Treatment
155
41
44
59
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Research Maturity
59 completed trials (38% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.3%
2 terminated out of 155 trials
96.7%
+10.2% vs benchmark
12%
19 trials in Phase 3/4
14%
8 of 59 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 59 completed trials
Clinical Trials (155)
Modulating Exercise Dosage to Improve Concussion Recovery
Multidimensional Sleep Health Intervention to Optimize Concussion Recovery
The Role of Platelet-rich Plasma Local Injection as Treatment in Improvement of Pilonidal Sinus Surgery Outcomes
Intrastromal Injection of Fluconazole in Treatment of Fungal Keratitis
Surgical Approach to Uterine Septum
Facilitators and Barriers to Eptinezumab Administration in Thailand
A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor
Brief Acceptance and Commitment Therapy for HIV-infected At-risk Drinkers
Treatment Response in Patients With Medication-Overuse Headache
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
A Trial of Chinese Traditional Medicine Combining With Intradermal Acupuncture for Treating Precocious Puberty
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Study of The Effects of Mandibular Advancement Aligners in Treating Children With Class II Division 1 Malocclusion
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
Clinical Study on the Effectiveness of Diverse Segments Defocus Optimization in Spectacle Lenses for Slowing Myopia Progression